STADA Arzneimittel AG
↗Bad Vilbel, Germany
STADA Arzneimittel AG is a leading international pharmaceutical company headquartered in Bad Vilbel, Germany. The company follows a three-pillar strategy consisting of Consumer Healthcare products (OTC), Generics, and Specialty Pharmaceuticals (including Biosimilars). STADA is one of the largest players in the European generics market and has significantly expanded its specialty portfolio in recent years.
Historically a cooperative of German pharmacists founded in 1895, STADA has transformed into a global healthcare platform. It is currently undergoing a major ownership transition, with private equity firms Bain Capital and Cinven selling a majority stake to CapVest Partners LLP in a deal valuing the company at approximately €10 billion ($11.7 billion). The company operates in over 120 countries and maintains a strong focus on sustainability and ESG initiatives.
CLASSIFICATION
Company Type:Pharma
Therapeutic Areas:
Industry:Pharmaceuticals
Sub-Industry:Generics, Specialty Pharma, and Consumer Healthcare
SIZE & FINANCIALS
Employees:10000+
Revenue:€4.0B - €4.5B
Founded:1895
Ownership:private
Status:operating
FUNDING
Stage:Acquired
Investors:CapVest Partners LLP, Bain Capital, Cinven, Elliott Management
PIPELINE
Stage:Commercial
Lead Drug Stage:Commercial
Modalities:Small molecule, Biosimilars, Monoclonal Antibodies (mAbs), Device-drug combinations
Active Trials:27
Trial Phases:Phase 1: 5 | Phase 2: 8 | Phase 3: 14
FDA Approvals:0
EMA Approvals:11
CORPORATE STRUCTURE
Parent Company:CapVest Partners LLP (Incoming)
Acquired By:CapVest Partners LLP (Majority stake acquisition announced Sept 2025, closing expected H1 2026) (2025-09-01)
Subsidiaries:Thornton & Ross (UK), Pymepharco (Vietnam), Hemofarm (Serbia), EG SpA (Italy)
Key Partnerships:Alvotech (Biosimilars development and commercialization), Bio-Thera Solutions (Golimumab and Tocilizumab biosimilars), Sanofi (Consumer healthcare brand acquisitions), Xbrane Biopharma (Ranibizumab biosimilar)
COMPETITION
Position:Leader
Competitors:Sandoz, Teva Pharmaceutical Industries, Viatris, Sun Pharma, Fresenius Kabi
LEADERSHIP
Key Executives:
Peter Goldschmidt - CEO
Boris Döbler - CFO
Simone Berger - Chief People Officer
Andreas Fibig - Chairman of the Board (Designate)
Board Members:Günter von Au (Current Chairman), Andreas Fibig (Incoming Chairman)
LINKS
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with STADA Arzneimittel AG. The information on this page was collected and compiled using AI agents from publicly available sources. While we strive for accuracy, this data may be incomplete, outdated, or contain errors. For official information, please visit the company's website directly. If you notice any inaccurate information, please contact us.